PreveCeutical Medical Inc. (PRVCF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.83 Million CAD | 18.81% |
| 2022 | 3.22 Million CAD | 10.74% |
| 2021 | 2.91 Million CAD | 2.0% |
| 2020 | 2.85 Million CAD | -39.5% |
| 2019 | 4.72 Million CAD | 31.59% |
| 2018 | 3.58 Million CAD | 36.75% |
| 2017 | 2.62 Million CAD | 1368.95% |
| 2016 | 178.59 Thousand CAD | 1733.96% |
| 2015 | -10.93 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 4.03 Million CAD | 5.17% |
| 2024 Q2 | 4.19 Million CAD | 4.11% |
| 2023 Q3 | 3.77 Million CAD | 5.26% |
| 2023 Q1 | 3.39 Million CAD | 5.37% |
| 2023 Q4 | 3.83 Million CAD | 1.5% |
| 2023 Q2 | 3.58 Million CAD | 5.53% |
| 2023 FY | 3.83 Million CAD | 18.81% |
| 2022 Q1 | 2.85 Million CAD | -2.12% |
| 2022 FY | 3.22 Million CAD | 10.74% |
| 2022 Q3 | 3.35 Million CAD | 12.86% |
| 2022 Q2 | 2.97 Million CAD | 4.2% |
| 2022 Q4 | 3.22 Million CAD | -3.8% |
| 2021 Q3 | 2.64 Million CAD | -5.22% |
| 2021 FY | 2.91 Million CAD | 2.0% |
| 2021 Q2 | 2.78 Million CAD | 11.34% |
| 2021 Q1 | 2.5 Million CAD | -12.4% |
| 2021 Q4 | 2.91 Million CAD | 10.34% |
| 2020 Q4 | 2.85 Million CAD | 4.22% |
| 2020 Q2 | 3.22 Million CAD | -32.12% |
| 2020 FY | 2.85 Million CAD | -39.5% |
| 2020 Q1 | 4.75 Million CAD | 0.65% |
| 2020 Q3 | 2.74 Million CAD | -15.03% |
| 2019 FY | 4.72 Million CAD | 31.59% |
| 2019 Q4 | 4.72 Million CAD | -4.25% |
| 2019 Q3 | 4.93 Million CAD | 3.6% |
| 2019 Q1 | 4.42 Million CAD | 23.22% |
| 2019 Q2 | 4.75 Million CAD | 7.66% |
| 2018 Q3 | 2.5 Million CAD | 168.9% |
| 2018 FY | 3.58 Million CAD | 36.75% |
| 2018 Q4 | 3.58 Million CAD | 43.44% |
| 2018 Q2 | 930.11 Thousand CAD | -72.98% |
| 2018 Q1 | 3.44 Million CAD | 31.22% |
| 2017 Q2 | 126.16 Thousand CAD | 171.22% |
| 2017 Q4 | 2.62 Million CAD | 36.14% |
| 2017 FY | 2.62 Million CAD | 1368.95% |
| 2017 Q1 | -177.13 Thousand CAD | -1482.92% |
| 2017 Q3 | 1.92 Million CAD | 1427.4% |
| 2016 Q3 | -15.57 Thousand CAD | -130.6% |
| 2016 Q2 | 50.9 Thousand CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | 178.59 Thousand CAD | 1733.96% |
| 2016 Q4 | 12.8 Thousand CAD | 182.24% |
| 2015 FY | -10.93 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 42.79 Million USD | 91.044% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 32.144% |
| CSL Limited | 10.52 Billion USD | 99.964% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 160.793% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -503.422% |
| BioStem Technologies, Inc. | 4.47 Million USD | 14.295% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 81.097% |
| Qrons Inc. | 351.42 Thousand USD | -990.622% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1635.43% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 91.176% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 70.072% |
| Skye Bioscience, Inc. | -5.72 Million USD | 166.99% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 18880.576% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1156.636% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -19191.992% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 292675.573% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.361% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -515.836% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 75.685% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 6.928% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -853.776% |
| SQZ Biotechnologies Company | -36.23 Million USD | 110.577% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -70.934% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -313.373% |
| Mesoblast Limited | 55.85 Million USD | 93.138% |
| Marizyme, Inc. | 18.56 Million USD | 79.36% |
| Genus plc | 190.6 Million USD | 97.989% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -71.423% |
| Pharming Group N.V. | 109.8 Million USD | 96.509% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -345.543% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -215.741% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -463.638% |
| ContraFect Corporation | -6.02 Million USD | 163.603% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -2746.679% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -231.716% |
| IMV Inc. | 7.67 Million USD | 50.033% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 30.338% |
| MultiCell Technologies, Inc. | 90.04 USD | -4256608.13% |
| ONE Bio Corp. | 9.04 Million USD | 57.603% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 622.187% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 70.394% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -180.177% |
| Q BioMed Inc. | 4.06 Million USD | 5.598% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 87.456% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -280.339% |
| Biomind Labs Inc. | 711.4 Thousand USD | -438.759% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 93.67% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -91.695% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -965.508% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2641.51% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -74.059% |
| GB Sciences, Inc. | 1.74 Million USD | -119.35% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2185.414% |
| HST Global, Inc. | 96.79 Thousand USD | -3859.728% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1758.596% |
| Halberd Corporation | 144.72 Thousand USD | -2548.365% |
| Enzolytics Inc. | 981.65 Thousand USD | -290.436% |
| Agentix Corp. | 37.63 Thousand USD | -10085.06% |
| Resverlogix Corp. | 6.45 Million USD | 40.587% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 669.425% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.189% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 108.153% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 45.796% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -41.502% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 143.357% |
| AVAX Technologies, Inc. | -5.9 Million USD | 164.926% |
| Zenith Capital Corp. | 10.06 Thousand USD | -37983.665% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1812.24% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -60.632% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2229.806% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 21023.354% |
| Kadimastem Ltd | -253.1 Thousand USD | 1614.306% |
| Helix BioMedix, Inc. | -2.57 Million USD | 249.132% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1804.429% |
| LadRx Corporation | -2.03 Million USD | 288.205% |
| Cell Source, Inc. | 9.23 Million USD | 58.484% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -503.422% |
| NovAccess Global Inc. | 2.17 Million USD | -75.938% |
| Affymax, Inc. | -5.59 Million USD | 168.478% |
| Itoco Inc. | 228.3 Thousand USD | -1578.781% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2718.419% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 22.68% |
| Mobile Lads Corp. | 484.23 Thousand USD | -691.509% |
| CytoDyn Inc. | 20.26 Million USD | 81.084% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 592486.399% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 41453.036% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 50.263% |
| SYBLEU INC | 473.71 Thousand USD | -709.083% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 14.007% |
| International Stem Cell Corporation | 2.59 Million USD | -47.982% |
| Bioxytran, Inc. | 1.89 Million USD | -101.839% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6040.932% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -75.741% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -11.612% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 55.188% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -396.079% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 406.619% |
| Neutra Corp. | 52.18 Thousand USD | -7244.243% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 253.987% |
| PureTech Health plc | -167.19 Million USD | 102.292% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1664.971% |
| IXICO plc | -4.44 Million USD | 186.234% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 71.006% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 93.012% |
| CSL Limited | 10.52 Billion USD | 99.964% |
| Cellectis S.A. | -43.81 Million USD | 108.747% |